NCT07340723招募中2 期
Novel First-line Therapies for Grade II Acute GVHD: a Randomized Controlled Trial
Daihong Liu1 个研究点 分布在 1 个国家目标入组 168 人开始时间: 2025年6月1日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 168
- 试验地点
- 1
- 主要终点
- Overall response rate (ORR) at Day 28
研究概览
简要总结
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )
详细描述
Acute graft-versus-host disease (GVHD) is treated with systemic corticosteroid immunosuppression as first line therapy. Many patients with grade II acute GVHD do not respond to primary therapy, high-dose systemic corticosteroids; therefore, survival for those patients remains particularly poor. Here we determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the Treatment of grade II acute GVHD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with hematological diseases.
- •Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.
- •New onset of grade II acute GVHD or intermediate or high risk aGVHD (based on modified GVHD Glucksberg criteria) within 100 days post-transplantation.
排除标准
- •Recipients of second allogeneic stem cell transplant.
- •Acute GVHD induced by donor lymphocyte infusion, interferon.
- •Received first line aGVHD treatment before enrollment.
- •Overlap GVHD syndrome.
- •Pregnant or breast-feeding women.
- •Pregnant or breast-feeding women.
- •Serum creatinine > 2.0 mg/dL or creatinine clearance < 40 mL/min measured or calculated by Cockroft-Gault equation.
- •Uncontrolled infection.
- •Human immunodeficiency virus infection.
- •Active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.
- •Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection.
- •Allergic history to Janus kinase inhibitors.
- •Severe organ dysfunction unrelated to underlying GVHD, including:
- •(1)Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction).
- •(2)Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.
- •(3)Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
- •14.Received Janus kinase inhibitor therapy after allo-HSCT for any indication. 15.Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.
结局指标
主要结局
Overall response rate (ORR) at Day 28
时间窗: Day 28 after treatment
Defined as the proportion of participants demonstrating a complete response (CR), or partial response (PR).
次要结局
- Six-month duration of response(Six-month after treatment)
- Duration of response(Day 90 after treatment)
- Nonrelapse mortality (NRM)(1 year after treatment)
- Cumulative incidence of relapse (CIR)(1 year after treatment)
- Disease-free survival (DFS)(1 year after treatment)
- Overall survival (OS)(1 year after treatment)
- GVHD-free and relapse-free survival (GRFS)(1 year after treatment)
- Recurrence of aGVHD(1 year after treatment)
- Failure-free survival(1 year after treatment)
研究者
Daihong Liu
Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication of Bone Marrow Transplants).2024-516064-28-00Equillium Inc.99
尚未招募
2 期
Golidocitinib Combined With GemOx in RR PTCLNCT07279584Ruijin Hospital31
招募中
1 期
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaNCT07311746M.D. Anderson Cancer Center36
尚未招募
不适用
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerNCT07294534Shanghai Henlius Biotech817
招募中
2 期
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerNCT07294508Shanghai Henlius Biotech706